{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:34:45Z","timestamp":1776720885065,"version":"3.51.2"},"reference-count":108,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hepatitis delta virus (HDV) infection requires the presence of hepatitis B virus (HBV), and chronic HBV\u2013HDV coinfection is considered the most severe form of viral hepatitis. When compared with HBV mono-infection, HBV\u2013HDV coinfection is associated with higher rates of liver cirrhosis and hepatocellular carcinoma (HCC). In this review, we aim to elucidate the complex relationship between HDV infection and the development of HCC. The exact mechanisms underlying the carcinogenic potential of HDV remain to be fully elucidated. Evidence suggests that HDV has both indirect and direct oncogenic effects. Indirect effects promote accelerated progression to liver cirrhosis, which results in a different tumor microenvironment. Direct oncogenic effects are suggested by a distinct molecular signature. The recent epidemiological data regarding HBV\u2013HDV coinfection should make us reconsider the HCC screening strategy, with special focus in younger non-cirrhotic patients. Finally, treating HCC in patients with chronic HDV poses unique challenges due to the complex interplay between HBV and HDV and the severity of liver disease. An in-depth understanding of the epidemiology and pathophysiology of HDV infection and carcinogenesis is essential to improve disease management in this high-risk population.<\/jats:p>","DOI":"10.3390\/cancers16223723","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T06:30:48Z","timestamp":1730788248000},"page":"3723","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Changing Face of Hepatitis Delta Virus Associated Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3670-5582","authenticated-orcid":false,"given":"Mariana Ferreira","family":"Cardoso","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Hospital Prof. Doutor Fernando Fonseca, 2720-276 Amadora, Portugal"},{"name":"Cl\u00ednica Universit\u00e1ria de Gastrenterologia, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-7860","authenticated-orcid":false,"given":"Mariana Verdelho","family":"Machado","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universit\u00e1ria de Gastrenterologia, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"},{"name":"Gastroenterology Department, Hospital de Vila Franca de Xira, 2600-009 Vila Franca de Xira, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"ref_1","unstructured":"(2024, July 21). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.who.int\/today."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gut.18.12.997","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers","volume":"18","author":"Rizzetto","year":"1977","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/323508a0","article-title":"Structure, sequence and expression of the hepatitis delta (delta) viral genome","volume":"323","author":"Wang","year":"1986","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: A systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tseligka, E.D., Clement, S., and Negro, F. (2021). HDV pathogenesis: Unravelling ariadne\u2019s thread. Viruses, 13.","DOI":"10.3390\/v13050778"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.07.005","article-title":"Prevalence and clinical course of hepatitis delta infection in greece: A 13-year prospective study","volume":"59","author":"Manesis","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Romeo, R., Foglieni, B., Casazza, G., Spreafico, M., Colombo, M., and Prati, D. (2014). High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092062"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijid.2018.07.005","article-title":"Epidemiology and clinical outcomes of hepatitis delta (D) virus infection in queensland, australia","volume":"74","author":"Coghill","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Binh, M.T., Hoan, N.X., Van Tong, H., Giang, D.P., Sy, B.T., Toan, N.L., Song, L.H., Bang, M.H., Wedemeyer, H., and Meyer, C.G. (2018). HDV infection rates in northern vietnam. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-26446-w"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.3748\/wjg.v20.i21.6457","article-title":"Virus-related liver cirrhosis: Molecular basis and therapeutic options","volume":"20","author":"Lin","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_16","first-page":"157","article-title":"Advances in hepatitis D virus biology and disease","volume":"12","author":"Smedile","year":"1994","journal-title":"Prog. Liver Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7326\/0003-4819-98-4-437","article-title":"Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment","volume":"98","author":"Rizzetto","year":"1983","journal-title":"Ann. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A 28-year study of the course of hepatitis delta infection: A risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1001\/jama.2023.23242","article-title":"Hepatitis D: A review","volume":"330","author":"Negro","year":"2023","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","article-title":"Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta","volume":"73","author":"Roulot","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jhep.2021.01.014","article-title":"The changing context of hepatitis D","volume":"74","author":"Rizzetto","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.31214","article-title":"Long-term study of hepatitis delta virus infection at secondary care centers: The impact of viremia on liver-related outcomes","volume":"72","author":"Kamal","year":"2020","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","article-title":"Outcome of chronic delta hepatitis in italy: A long-term cohort study","volume":"53","author":"Niro","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2893.2010.01324.x","article-title":"Clinical outcome of acute and chronic hepatitis delta over time: A long-term follow-up study","volume":"18","author":"Buti","year":"2011","journal-title":"J. Viral Hepat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/ueg2.12163","article-title":"Hepatitis D virus (HDV) prevalence in austria is low but causes considerable morbidity due to fast progression to cirrhosis","volume":"9","author":"Jachs","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s12072-023-10575-0","article-title":"Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection","volume":"17","author":"Wranke","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2023). EASL clinical practice guidelines on hepatitis delta virus. J. Hepatol., 79, 433\u2013460.","DOI":"10.1016\/j.jhep.2023.05.001"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/HEP.0000000000000642","article-title":"Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis","volume":"79","author":"Gish","year":"2024","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The european concerted action on viral hepatitis (eurohep)","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2015.04.025","article-title":"Delta hepatitis within the veterans affairs medical system in the united states: Prevalence, risk factors, and outcomes","volume":"63","author":"Kushner","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Bockmann, J.H., Grube, M., Hamed, V., von Felden, J., Landahl, J., Wehmeyer, M., Giersch, K., Hall, M.T., Murray, J.M., and Dandri, M. (2020). High rates of cirrhosis and severe clinical events in patients with HBV\/HDV co-infection: Longitudinal analysis of a german cohort. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-1168-9"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/apt.15188","article-title":"Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir","volume":"49","author":"Brancaccio","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jmv.21078","article-title":"The increasing prevalence of hepatitis delta virus (HDV) infection in south london","volume":"80","author":"Cross","year":"2008","journal-title":"J. Med. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/JCMA.0000000000000606","article-title":"Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis","volume":"85","author":"Chang","year":"2022","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jvh.13577","article-title":"Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies","volume":"28","author":"Kamal","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S1053","DOI":"10.1016\/S0016-5085(24)02892-0","article-title":"Hepatitis B versus hepatitis B delta co-infection and risk of hepatocellular carcinoma in non-cirrhotic liver","volume":"166","author":"Amakye","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/liv.15855","article-title":"Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma","volume":"44","author":"Giannini","year":"2024","journal-title":"Liver Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/liv.15882","article-title":"Delta virus infection and hepatocellular carcinoma","volume":"44","author":"Bonacini","year":"2024","journal-title":"Liver Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijid.2023.02.006","article-title":"Trends in chronic hepatitis B virus infection in italy over a 10-year period: Clues from the nationwide piter and master cohorts toward elimination","volume":"129","author":"Brancaccio","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wedemeyer, H., Leus, M., Battersby, T.R., Glenn, J., Gordien, E., Kamili, S., Kapoor, H., Kessler, H.H., Lenz, O., and Lutgehetmann, M. (Hepatology, 2023). HDV RNA assays: Performance characteristics, clinical utility, and challenges, Hepatology, Epub ahead of print.","DOI":"10.1097\/HEP.0000000000000584"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jnci\/djs168","article-title":"A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma","volume":"104","author":"Ji","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2016.10.007","article-title":"Hepatitis delta-associated mortality in hiv\/hbv-coinfected patients","volume":"66","author":"Beguelin","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/jmv.20755","article-title":"High frequency of hepatocellular carcinoma in mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses","volume":"78","author":"Oyunsuren","year":"2006","journal-title":"J. Med. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4254\/wjh.v11.i1.1","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review","volume":"11","author":"Desai","year":"2019","journal-title":"World J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2006.10.038","article-title":"Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: Implication of hepatitis delta virus-induced liver fibrosis","volume":"132","author":"Choi","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10059-009-0100-5","article-title":"Hepatitis delta virus large antigen sensitizes to TNF-alpha-induced NF-kappaB signaling","volume":"28","author":"Park","year":"2009","journal-title":"Mol. Cells"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jhep.2015.03.011","article-title":"Hepatitis delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to hbv mono-infection","volume":"63","author":"Giersch","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/path.4434","article-title":"The direct and indirect roles of HBV in liver cancer: Prospective markers for HCC screening and potential therapeutic targets","volume":"235","author":"Ringelhan","year":"2015","journal-title":"J. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2016.10.006","article-title":"HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes","volume":"136","author":"Alfaiate","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0168-8278(91)90918-2","article-title":"Why most patients with hepatitis delta virus infection are seronegative for hepatitis B e antigen. A prospective controlled study","volume":"12","author":"Liaw","year":"1991","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Padarath, K., Deroubaix, A., and Kramvis, A. (2023). The complex role of HBeAg and its precursors in the pathway to hepatocellular carcinoma. Viruses, 15.","DOI":"10.3390\/v15040857"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1541-7786.MCR-18-0012","article-title":"Molecular signature and mechanisms of hepatitis D virus-associated hepatocellular carcinoma","volume":"16","author":"Diaz","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Yu, Z., Ma, X., Zhang, W., Chang, X., An, L., Niu, M., Chen, Y., Sun, C., and Yang, Y. (2021). Microarray data mining and preliminary bioinformatics analysis of hepatitis D virus-associated hepatocellular carcinoma. BioMed Res. Int., 2021.","DOI":"10.1155\/2021\/1093702"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1038\/s41467-020-18186-1","article-title":"The genomic landscape of mongolian hepatocellular carcinoma","volume":"11","author":"Candia","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhepr.2019.05.001","article-title":"The oncogenic role of hepatitis delta virus in hepatocellular carcinoma","volume":"1","author":"Puigvehi","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1128\/jvi.68.2.1052-1058.1994","article-title":"Expression of the hepatitis delta virus large and small antigens in transgenic mice","volume":"68","author":"Guilhot","year":"1994","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2893.2012.01597.x","article-title":"Large hepatitis delta antigen activates stat-3 and NF-kappaB via oxidative stress","volume":"19","author":"Williams","year":"2012","journal-title":"J. Viral Hepat."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1139\/bcb-2017-0321","article-title":"Small hepatitis delta antigen selectively binds to target mrna in hepatic cells: A potential mechanism by which hepatitis d virus downregulates glutathione s-transferase p1 and induces liver injury and hepatocarcinogenesis","volume":"97","author":"Chen","year":"2019","journal-title":"Biochem. Cell Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/CEJ.0000000000000121","article-title":"Association of APC, GSTP1 and SOCS1 promoter methylation with the risk of hepatocellular carcinoma: A meta-analysis","volume":"24","author":"Liu","year":"2015","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.4103\/0973-1482.181179","article-title":"Clinical significance and association of GSTP1 hypermethylation with hepatocellular carcinoma: A meta-analysis","volume":"14","author":"Li","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Chen, Y.L., Tseng, H.S., Kuo, W.H., Yang, S.F., Chen, D.R., and Tsai, H.T. (2010). Glutathione s-transferase p1 (GSTP1) gene polymorphism increases age-related susceptibility to hepatocellular carcinoma. BMC Med. Genet., 11.","DOI":"10.1186\/1471-2350-11-46"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s13277-015-3871-7","article-title":"Glutathione s-transferase p1 gene rs4147581 polymorphism predicts overall survival of patients with hepatocellular carcinoma: Evidence from an enlarged study","volume":"37","author":"Wang","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_65","first-page":"2585","article-title":"Overview of the STAT-3 signaling pathway in cancer and the development of specific inhibitors","volume":"19","author":"Gu","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.febslet.2013.03.021","article-title":"Hepatitis delta virus induces specific DNA methylation processes in huh-7 liver cancer cells","volume":"587","author":"Benegiamo","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.semcancer.2021.07.017","article-title":"Epigenetics in hepatocellular carcinoma","volume":"86","author":"Nagaraju","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Denechaud, P.D., Fajas, L., and Giralt, A. (2017). E2f1, a novel regulator of metabolism. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00311"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"115767","DOI":"10.1016\/j.envres.2023.115767","article-title":"Multifaceted role of NF-kappaB in hepatocellular carcinoma therapy: Molecular landscape, therapeutic compounds and nanomaterial approaches","volume":"228","author":"Gupta","year":"2023","journal-title":"Environ. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jprot.2013.06.002","article-title":"Proteomic changes in hek-293 cells induced by hepatitis delta virus replication","volume":"89","author":"Mendes","year":"2013","journal-title":"J. Proteom."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1111\/febs.15352","article-title":"Hepatitis delta virus interacts with splicing factor SF3B155 and alters pre-mRNA splicing of cell cycle control genes","volume":"287","author":"Tavanez","year":"2020","journal-title":"FEBS J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/cbin.11649","article-title":"LncRNA RBM5-AS1 promotes cell proliferation and invasion by epigenetically silencing mir-132\/212 in hepatocellular carcinoma cells","volume":"45","author":"Mu","year":"2021","journal-title":"Cell Biol. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1099\/vir.0.007211-0","article-title":"Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells","volume":"90","author":"Liao","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.humpath.2004.07.021","article-title":"Overexpression of clusterin in human hepatocellular carcinoma","volume":"35","author":"Kang","year":"2004","journal-title":"Hum. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8262","DOI":"10.3748\/wjg.v21.i27.8262","article-title":"Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma","volume":"21","author":"Xiu","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/sj.onc.1209141","article-title":"Clusterin plays an important role in hepatocellular carcinoma metastasis","volume":"25","author":"Lau","year":"2006","journal-title":"Oncogene"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12967-016-1085-4","article-title":"Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology","volume":"14","author":"Zhang","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Gonzalez-Sanchez, E., Vaquero, J., Fernandez-Barrena, M.G., Lasarte, J.J., Avila, M.A., Sarobe, P., Reig, M., Calvo, M., and Fabregat, I. (2021). The tgf-beta pathway: A pharmacological target in hepatocellular carcinoma?. Cancers, 13.","DOI":"10.3390\/cancers13133248"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Guo, Y., Zhu, J., Xu, X., Shen, B., Shen, Z., Li, B., Li, F., Gu, T., Cai, X., and Dong, H. (2022). Tgf-beta\/yb-1\/atg7 axis promotes the proliferation of hepatic progenitor cells and liver fibrogenesis. Biochim. Biophys. Acta Mol. Basis Dis., 1868.","DOI":"10.1016\/j.bbadis.2021.166290"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/hep.26007","article-title":"Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development","volume":"56","author":"Wu","year":"2012","journal-title":"Hepatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"37311","DOI":"10.1074\/jbc.M002947200","article-title":"Large isoform of hepatitis delta antigen activates serum response factor-associated transcription","volume":"275","author":"Goto","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1086\/368389","article-title":"Synergistic activation of the serum response element-dependent pathway by hepatitis B virus X protein and large-isoform hepatitis delta antigen","volume":"187","author":"Goto","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/infdis\/jiw514","article-title":"The third signal cytokine interleukin 12 rather than immune checkpoint inhibitors contributes to the functional restoration of hepatitis d virus-specific t cells","volume":"215","author":"Schirdewahn","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/BF01297460","article-title":"Role of hepatitis delta virus infection in hepatocellular carcinoma","volume":"36","author":"Verme","year":"1991","journal-title":"Dig. Dis. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0168-8278(05)80629-4","article-title":"Incidence and risk factors of acute delta hepatitis in italy: Results from a national surveillance system. Seieva collaborating group","volume":"21","author":"Stroffolini","year":"1994","journal-title":"J. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0168-8278(96)80202-9","article-title":"Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection","volume":"25","author":"Huo","year":"1996","journal-title":"J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1440-1746.1997.tb00364.x","article-title":"Decreasing hepatitis D virus infection in taiwan: An analysis of contributory factors","volume":"12","author":"Huo","year":"1997","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/1319-3767.91731","article-title":"Hepatocellular carcinoma in hepatitis D: Does it differ from hepatitis B monoinfection?","volume":"18","author":"Abbas","year":"2012","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Jang, T.Y., Wei, Y.J., Liu, T.W., Yeh, M.L., Liu, S.F., Hsu, C.T., Hsu, P.Y., Lin, Y.H., Liang, P.C., and Hsieh, M.H. (2021). Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide\/nucleoside analogues. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-87679-w"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver-related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S0168-8278(24)00561-0","article-title":"Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: A case control study with propensity score weighted analysis","volume":"80","author":"Degasperi","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"Page-B predicts the risk of developing hepatocellular carcinoma in caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_95","unstructured":"European Association for the Study of the Liver (2018). EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e0334","DOI":"10.1097\/HC9.0000000000000334","article-title":"Age-specific and sex-specific risks for HCC in african-born persons with chronic hepatitis B without cirrhosis","volume":"7","author":"Kamal","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/apt.16374","article-title":"2020 position statement and recommendations of the european liver and intestine transplantation association (ELITA): Management of hepatitis B virus-related infection before and after liver transplantation","volume":"54","author":"Duvoux","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2013.11.010","article-title":"Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection","volume":"60","author":"Giersch","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jhep.2024.01.035","article-title":"Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies","volume":"80","author":"Allweiss","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/hep.28266","article-title":"Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation","volume":"63","author":"Lee","year":"2016","journal-title":"Hepatology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12072-023-10618-6","article-title":"Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: A meta-analysis","volume":"18","author":"Luo","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.2147\/OTT.S150281","article-title":"The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: A systematic review and meta-analysis","volume":"10","author":"Chen","year":"2017","journal-title":"Oncol. Targets Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_106","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (ibi305) versus sorafenib in unresectable hepatocellular carcinoma (orient-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jhep.2022.01.017","article-title":"Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection","volume":"77","author":"Jachs","year":"2022","journal-title":"J. Hepatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/22\/3723\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:26:19Z","timestamp":1760113579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/22\/3723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":108,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["cancers16223723"],"URL":"https:\/\/doi.org\/10.3390\/cancers16223723","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]}}}